TLOG (TetraLogic Pharmaceuticals) Return-on-Tangible-Equity: 0.00% (As of Sep. 2016)


What is TetraLogic Pharmaceuticals Return-on-Tangible-Equity?

TetraLogic Pharmaceuticals TLOG Return-on-Tangible-Equity is 0.00% as of Sep. 2016.

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. TetraLogic Pharmaceuticals's annualized net income for the quarter that ended in Sep. 2016 was $-34.54 Mil. TetraLogic Pharmaceuticals's average shareholder tangible equity for the quarter that ended in Sep. 2016 was $-65.59 Mil. Therefore, TetraLogic Pharmaceuticals's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2016 was N/A%.

The historical rank and industry rank for TetraLogic Pharmaceuticals's Return-on-Tangible-Equity or its related term are showing as below:

TLOG's Return-on-Tangible-Equity is not ranked *
in the Biotechnology industry.
Industry Median: -42.21
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

TetraLogic Pharmaceuticals  (OTCPK:TLOG) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.

Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.

TetraLogic Pharmaceuticals Return-on-Tangible-Equity Related Terms

TetraLogic Pharmaceuticals Return-on-Tangible-Equity Historical Data

* Premium members only.

The historical data trend for TetraLogic Pharmaceuticals's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TetraLogic Pharmaceuticals Return-on-Tangible-Equity Chart

TetraLogic Pharmaceuticals Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15
Return-on-Tangible-Equity
0.00 0.00 0.00 -282.33 0.00

TetraLogic Pharmaceuticals Quarterly Data
Dec11 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TLOG vs ARGSQ, GTHR, SOAN: Return-on-Tangible-Equity Comparison

For the Biotechnology subindustry, TetraLogic Pharmaceuticals's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TetraLogic Pharmaceuticals Return-on-Tangible-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TetraLogic Pharmaceuticals's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where TetraLogic Pharmaceuticals's Return-on-Tangible-Equity falls into.


TetraLogic Pharmaceuticals Return-on-Tangible-Equity Calculation

TetraLogic Pharmaceuticals's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2015 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2015 )  (A: Dec. 2014 )(A: Dec. 2015 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2015 )  (A: Dec. 2014 )(A: Dec. 2015 )
=-49.724/( (-25.076+-47.517 )/ 2 )
=-49.724/-36.2965
=N/A %

TetraLogic Pharmaceuticals's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2016 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Sep. 2016 )  (Q: Jun. 2016 )(Q: Sep. 2016 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Sep. 2016 )  (Q: Jun. 2016 )(Q: Sep. 2016 )
=-34.54/( (-63.831+-67.345)/ 2 )
=-34.54/-65.588
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2016) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.

What does a Return-on-Tangible-Equity of 0.00% mean?
TetraLogic Pharmaceuticals (TLOG) has a Return-on-Tangible-Equity of 0.00% as of Sep. 2016. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on TetraLogic Pharmaceuticals and its competitors.
Is TetraLogic Pharmaceuticals' Return-on-Tangible-Equity too high?
TetraLogic Pharmaceuticals' current Return-on-Tangible-Equity is 0.00%.
How does TetraLogic Pharmaceuticals' Return-on-Tangible-Equity compare to ARGSQ and GTHR?
TetraLogic Pharmaceuticals' Return-on-Tangible-Equity of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on TetraLogic Pharmaceuticals and its competitors. TetraLogic Pharmaceuticals's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TetraLogic Pharmaceuticals stock overvalued right now?
TetraLogic Pharmaceuticals (TLOG) has a current Return-on-Tangible-Equity of 0.00%. The current Return-on-Tangible-Equity is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For TetraLogic Pharmaceuticals (TLOG), the current Return-on-Tangible-Equity is 0.00% as of Sep. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TetraLogic Pharmaceuticals Business Description

Address 343 Phoenixville Pike, Malvern, PA, USA, 19355
TetraLogic Pharmaceuticals Corp is a biopharmaceutical company. The company is engaged in developing novel small molecule therapeutics in oncology.